AJMC September 11, 2025
Key Takeaways
- The transition from OCM to EOM has been challenging, with many practices not receiving expected performance bonuses due to narrow parameters and specific cancer type focus.
- Drug pricing changes and the rise of expensive biosimilars have disrupted cost-of-care savings, impacting EOM performance results.
- Data lag remains a significant issue, hindering practices’ ability to learn from performance results and adapt in real time.
- Administrative burdens and varying program requirements among payers add complexity to participating in the EOM, prompting practices to reconsider their involvement.
Community oncology leaders navigate challenges in value-based care under the Enhancing Oncology Model, facing performance payment uncertainties and evolving drug markets.
Few leaders in community oncology have rallied for value-based care more than...
Today's Sponsors
Today's Sponsor